Inhibition of CFU-E Colony Formation in Uremic Patients with Inflammatory Disease: Role of IFN-γ and TNF-α

Journal of Investigative Medicine

Volumn 47, Issue 5, 1999, Pages 204-211

  Allen, David A ^a   Breen, Cormac ^b   Yaqoob, Muhammad M ^a   Macdougall, Iain C ^b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Anemia of chronic disease; Bone marrow; Cytokines; Erythropoietin; Renal disease

Indexed keywords

AUTACOID; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLONOGENIC ASSAY; ERYTHROPOIESIS; FEMALE; HUMAN; IN VITRO STUDY; INFECTION; INFLAMMATION; MALE; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; UREMIA;

ADULT; AGED; COLONY-FORMING UNITS ASSAY; ERYTHROPOIESIS; FEMALE; HUMANS; INFECTION; INFLAMMATION; INFLAMMATION MEDIATORS; INTERFERON TYPE II; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; UREMIA;

EID: 0033128905     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Eschbach JW, Downing RW, Egrie JC, Browne JK, Adamson JW. USA multicenter trial with recombinant human erythropoietin (Amgen). Results in hemodialysis patients. Contrib Nephrol 1989;76:160-5.
2. Sundal E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 1989;4:979-87.
3. Macdougall IC. Poor response to erythropoietin. Br Med J 1995;310:1424-5.
4. Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. Br Med J 1989;299:157-8.
5. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989;35:712-6.
6. Muirhead N, Hodsman AB. Occult infection and resistance of anaemia to rHu EPO therapy in renal failure. Nephrol Dial Transplant 1990;5:232-4.
7. Macdougall IC, Allen DA, Tucker B, Baker LRI, Raine AEG. Serum interleukin-6 levels are a useful indicator of marrow suppression in patients with resistance to erythropoietin due to inflammatory disease [abstract]. J Am Soc Nephrol 1993;4:428A.
8. Means RT Jr, Krantz SB. Inhibition of human erythroid colony forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 1991;78:2564-7.
9. Means RT Jr, Krantz SB. Inhibition of human erythroid colony forming units by tumor necrosis factor requires beta interferon. J Clin Invest 1993;91:416-9.
10. Zoumbos NF, Djeu JY, Young NS. Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. J Immunol 1984;133:769-74.
11. Dybedal I, Jacobsen SE. Transforming growth factor beta (TGF-β), a potent inhibitor of erythropoiesis: neutralizing TGF-β antibodies show erythropoietin as a potent stimulator of murine burst-forming unit erythroid colony formation in the absence of a burst-promoting activity. Blood 1995;86:949-57.
12. Baer AN, Dessypris EN, Goldwasser E, Krantz SB. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol 1987;66:559-64.
13. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639-47.
14. Schaefer RM, Paczek L, Heidland A. Cytokine production by monocytes during hemodialysis. Nephrol Dial Transplant 1991;(2 Suppl)6:14-7.
15. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Influence of first and long-term dialysis on uremia-associated increased basal production of interleukin-1 and tumor necrosis factor-α by circulating monocytes. Nephrol Dial Transplant 1991;6:349-57.
16. Erturk S, Ates K, Duman N, Tutkak H, Ayli D, Karatan O, Erbay B, Ertug E. Serum cytokine levels in uremic patients. Nephron 1996;72:492.
17. Gafter U, Kalechman Y, Orlin JB, Levi J, Sredni B. Anemia of uremia is associated with reduced in vitro cytokine secretion: immunopotentiating activity of red blood cells. Kidney Int 1994;45:224-31.
18. Sutherland HJ, Eaves AC, Eaves CJ. In: Bone marrow processing and purging: a practical guide. Boca Raton: CRC Press Inc, 1991:155-71.
19. Eaves CJ, Eaves AC. Erythropoietin (Ep) dose-response curves for three classes of erythroid progenitors in normal marrow and in patients with polycythemia vera. Blood 1978;52:1196-210.
20. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 1984;25:437-44.
21. Hotta T, Maeda H, Suzuki I, Chung TG, Saito A. Selective inhibition of erythropoiesis by sera from patients with chronic renal failure. Proc Soc Exp Biol Med 1987;186:47-51.
22. Ludwig H, Fritz E, Kotzman H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-9.
23. Caillete A, Barreto S, Gimenez E, Labeeuw M, Zech P. Is erythropoietin treatment safe and effective in myeloma patients receiving hemodialysis? Clin Nephrol 1993;40(3):176-8.
24. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993;328(3):171-5.
25. Wallner SF, Kurnick JE, Ward HP, Vautrin R, Alfrey AC. The anemia of chronic renal failure and chronic diseases: in vitro studies of erythropoiesis. Blood 1976;47(4):561-9.
26. Bozzini CE, Devoto FC, Tomio JM. Decreased responsiveness of hematopoietic tissue to erythropoietin in acutely uremic rats. J Lab Clin Med 1966;68(3):411-7.
27. McGonigle RJ, Husserl F, Wallin JD, Fisher JW. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. Kidney Int 1984;25(2):430-6.
28. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 1984;25(2):437-44.
29. Ifudu O, Feldman J, Freidman EA. The intensity of dialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996;334(7):420-5.
30. Worrall J, Allen DA, Raftery MJ, Yaqoob MM. Impaired iron utilization and duration of hemodialysis are principal factors in erythropoietin resistance [abstract]. J Am Soc Nephrol 1997;8:225A.
31. Meytes D, Bogin E, Ma A, Dukes PP, Massry SG. Effects of parathyroid hormone on erythropoiesis. J Clin Invest 1981;67:1263-9.
32. Freedman MH, Saunders EF, Cattran DF, Rabin EZ. Ribonuclease inhibition of erythropoiesis in anemia of uremia. Am J Kid Dis 1983;2:530-3.
33. Kushner D, Beckman B, Nguyen L, Chen S, Della Santina C, Husserl F, Rice J, Fisher JW. Polyamines in the anemia of end-stage renal disease. Kidney Int 1991;39(4):725-32.
34. Friedlander MA, Witko-Sarsat V, Nguyen AT, Wu YC, Labrunte M, Verger C, Jungers P, Deschamps-Latscha B. The advanced glycation endproduct pentosidine and monocyte activation in uremia. Clin Nephrol 1996;45(6):379-82.
35. Wallner SF, Vautrin RM, Kurnick JE, Ward HP. The effect of serum from patients with chronic renal failure on erythroid colony growth in vitro. J Lab Clin Med 1978;92(3):370-5.
36. Schaefer RM, Paczek L, Heidland A. Cytokine production by monocytes during hemodialysis. Nephrol Dial Transplant 1991;6(Suppl 2):14-7.
37. Herbelin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Influence of first and long-term dialysis on uremia-associated increased basal production of interleukin-1 and tumor necrosis factor a by circulating monocytes. Nephrol Dial Transplant 1991;6:349-57.
38. Heberlin A, Urena P, Nguyen AT, Zingraff J, Descamps-Latscha B. Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991;39:954-60.
39. Cassidy MJD, DeJager C, Ebrahim O, Camachio P, Robson S. Peripheral blood mononuclear cells from patients with chronic renal failure release factors which suppress erythropoietin secretion in vitro. Nephrol Dial Transplant 1994;9:775-9.
40. Means RT Jr, Krantz SB. Inhibition of human erythoid colony-forming units by interferons α and β: differing mechanisms despite shared receptor. Exp Hematol 1996;24:204-8.
41. Selleri C, Maciejewski JP, Sato T, Young NS. Interferon-gamma constitutively expressed in the stromal microenvironment of human bone marrow cultures mediates potent hematopoietic inhibition. Blood 1996;87:4149-57.
42. Gutman RA, Huang AT. Inhibitor of marrow thymidine incorporation from sera of patients with uremia. Kidney Int 1980;18:715-24.
43. Konijn AM, Hershko C. The anemia of inflammation and chronic disease. In: de Sousa M, Brock JH, eds. Iron in immunity, cancer and inflammation. Wiley; 1989:111-43.
44. Cory S, Maekawa T, McNeall J, Metcalf D. Murine erythroid cell lines derived with c-myc retroviruses respond to leukemia-inhibitory factor, erythropoietin and interleukin-3. Cell Growth Differ 1991;2:165-72.
45. Shimizu R, Komatsu N, Nakamura Y, Nakauchi H, Nakabeppu Y, Miura Y. Role of c-jun in the inhibition of erythropoietin receptor-mediated apoptosis. Biochem Biophys Res Commun 1996;222:1-6.
46. L and Bcl-2. Blood 1996;88:1576-82.
47. Taniguchi S, Dai CH, Price JO, Krantz SB. Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. Blood 1997;90:2244-52.
48. Komatsu N, Kirito K, Kashii Y, Furukawa Y, Kikuchi J, Suwabe N, Yamamoto M, Miura Y. Cell cycle-dependent regulation of the erythropoietin receptor gene. Blood 1997;89:1182-8.
49. Lee GR. The anemia of chronic disease. Semin Hematol 1983;20:61-80.